A recent study reveals that patients who come off new slimming jabs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional lifestyle plans.
Findings released in a major medical journal points out that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such drugs need to be cognizant of the danger of rapid rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
Such speed of regain implies a return to original weight in about a year and a half.
Weighing Approaches
The study, which looked at dozens of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods.
Scientists emphasize that individuals who shed pounds through lifestyle changes alone usually experience a less rapid creep back—around 0.1 kg a month—after stopping.
Explaining the Fast Rebound
Experts suggest the mechanism of the injections is key to understanding the amplified regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels far above than normal may cause the system to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."
A Lifelong Issue?
The NHS recommend the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, considering the high risk of weight regain, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the persistent nature of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Individuals who have discontinued the jabs report a intense resurgence of cravings.
"I experienced a trigger that goes on and you become ravenous," said one woman.
This challenge is exacerbated if individuals have not developed permanent lifestyle or habit modifications during treatment.
Significant Adoption
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is higher among females compared to men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, experts caution that while these medications are effective tools for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle management.
